Braunwald’s Heart Disease, 2 Vol Set
A Textbook of Cardiovascular Medicine
- 12th Edition - October 15, 2021
- Author: Peter Libby
- Editors: Robert O. Bonow, Douglas L. Mann, Gordon F. Tomaselli, Deepak L. Bhatt, Scott D. Solomon, Eugene Braunwald
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 7 2 2 1 9 - 3
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 8 2 4 6 7 - 5
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 8 2 4 6 8 - 2
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 8 2 4 7 1 - 2
**Selected for Doody’s Core Titles® 2024 with "Essential Purchase" designation in Cardiology**Current, comprehensive, and evidence-based Braunwald’s Heart Disease remains the… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quote**Selected for Doody’s Core Titles® 2024 with "Essential Purchase" designation in Cardiology**
Current, comprehensive, and evidence-based Braunwald’s Heart Disease remains the most trusted reference in the field and the leading source of reliable cardiology information for practitioners and trainees worldwide. The fully updated 12th Edition continues the tradition of excellence with dependable, state-of-the-art coverage of new drugs, new guidelines, more powerful imaging modalities, and recent developments in precision medicine that continue to change and advance the practice of cardiovascular medicine. Written and edited by global experts in the field, this award-winning text is an unparalleled multimedia reference for every aspect of this complex and fast-changing area.
- Offers balanced, dependable content on rapidly changing clinical science, clinical and translational research, and evidence-based medicine.
- Includes 76 new contributing authors and 14 new chapters that cover Artificial intelligence in Cardiovascular Medicine; Wearables; Influenza, Pandemics, COVID-19, and Cardiovascular Disease; Tobacco and Nicotine Products in Cardiovascular Disease; Cardiac Amyloidosis; Impact of the Environment on Cardiovascular Health, and more.
- Features a new introductory chapter Cardiovascular Disease: Past, Present, and Future by Eugene Braunwald, MD, offering his unique, visionary approach to the field of cardiology. Dr. Braunwald also curates the extensive, bimonthly online updates that include "Hot Off the Press" (with links to Practice Update) and "Late-Breaking Clinical Trials".
- Provides cutting-edge coverage of key topics such as proteomics and metabolomics, TAVR, diabetocardiology, and cardio-oncology.
- Contains 1,850 high-quality illustrations, radiographic images, algorithms, and charts, and provides access to 215 videos called out with icons in the print version.
- Highlights the latest AHA, ACC, and ESC guidelines to clearly summarize diagnostic criteria and clinical implications.
- Provides tightly edited, focused content for quick, dependable reference. Flexible format options include either one or two volumes in print, as well as a searchable eBook with ongoing updates.
- Enhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices.
Practicing cardiologists and fellows
- Instructions for online access
- Cover image
- Title page
- Table of Contents
- Copyright
- Dedication
- Contributors
- Preface
- Preface to the First Edition
- Acknowledgments
- Part I. Foundations of Cardiovascular Medicine
- 1. Cardiovascular Disease: Past, Present, and Future
- The Birth
- Cardiac Imaging (see Part III)
- Invasive Procedures (see Chapters 21, 22, and 41)
- Hypertension (see Chapter 26)
- Valvular Heart Disease (see Part VIII)
- Arrhythmias (see Part VII)
- Dyslipidemias (see Chapters 25 and 27)
- Acute Myocardial Infarction (see Chapters 37 to 39)
- Heart Failure (see Part VI)
- Assisted Circulation (see Chapter 58)
- Genomics and Genetics (see Chapter 7)
- Primordial Prevention (see Chapter 25)
- Inflammation (see Chapter 24)
- Clonal Hematopoiesis (see Chapter 24)
- Artificial Intelligence (see Chapter 11)
- Conclusions
- 2. Global Burden of Cardiovascular Disease
- Shifting Burden
- Epidemiologic Transitions
- Current Variations in the Global Burden
- Risk Factors
- Economic Burden
- Cost-Effective Solutions
- Summary and Conclusion
- 3. Impact of the Environment on Cardiovascular Health
- Global Footprint and Impact of Pollutants on Human Health
- Air Pollution
- Climate Change
- Noise Pollution and Cardiovascular Disease
- Synthetic Chemicals and Cardiovascular Disease
- Metallic Pollutants and Cardiovascular Disease
- Challenges and Outlook For the Future
- 4. Clinical Trials in Cardiovascular Medicine
- Clinical Trials Versus Other Types of Studies
- Components of Clinical Trials
- Statistical Considerations in Trials
- Ethical Considerations and Informed Consent
- Monitoring of Data and Data Safety
- Novel Approaches to Clinical Trial Design and Execution
- Interpretation of Clinical Trials
- Conclusion
- 5. Clinical Decision-Making in Cardiology
- Diagnostic Decisions
- Therapeutic Decisions
- Deciding When to Change Clinical Practice Based on New Clinical Research Findings
- Shared Decision-Making
- Monitoring the Quality of Clinical Decisions
- Teaching Clinical Reasoning
- Conclusion
- 6. Impact of Health Care Policy on Quality, Outcomes, and Equity in Cardiovascular Disease
- What is Health Policy?
- Insurance Coverage and Access Policy
- Payment and Delivery System Policy to Improve Quality and Reduce Costs
- Inequities in Cardiovascular Disease Risk, Care, and Outcomes
- Conclusions
- Part II. Individualizing Approaches to Cardiovascular Disease
- 7. Applications of Genetics to Cardiovascular Medicine
- Key Principles of Human Genetics
- Gene Discovery
- Causal Inference of Epidemiologic Associations
- Disease Risk Prediction
- Therapeutic Response Prediction
- Next-Generation Technologies and Therapeutics
- Future Perspectives
- 8. Proteomics and Metabolomics in Cardiovascular Medicine
- Novel Technologies in the Identification of Biomarkers
- Introduction to Proteomics and Metabolomics
- Analytic Challenges For Proteomics and Metabolomics
- Overview of the Discovery Process
- Applications of Mass Spectrometry–Based Discovery to Cardiometabolic Disease
- Future Directions in Biomarker Discovery
- 9. Principles of Drug Therapeutics, Pharmacogenomics, and Biologics
- Risk Versus Benefit of Drug Therapy
- Pharmacokinetics and Pharmacodynamics
- Molecular and Genetic Basis for Variable Drug Response
- Optimizing Drug Doses
- Future Perspectives
- 10. Biomarkers and Use in Precision Medicine
- Overview of Biomarkers
- Clinical Measures of Biomarker Performance
- Conclusion
- 11. Artificial Intelligence in Cardiovascular Medicine
- Definitions and Key Terms
- Clinical Uses in Cardiovascular Medicine
- Implementing Artificial Intelligence Into Clinical Practice
- Conclusions
- 12. Wearable Devices in Cardiovascular Medicine
- Definitions and Overview
- Activity and Heart Rate Tracking for General Cardiovascular Wellness
- Atrial Fibrillation
- Hypertension
- Cardiac Rehabilitation and Heart Failure
- Cardiac Arrest and Sudden Cardiac Death
- Evaluation of Wearable Data and Notifications
- Limitations
- The Future
- Part III. Evaluation of The Patient
- 13. History and Physical Examination: An Evidence-Based Approach
- The History
- The General Physical Examination
- The Cardiovascular Examination
- Integrated, Evidence-Based Approach to Specific Cardiac Disorders
- Future Directions
- 14. Electrocardiography
- The Normal Electrocardiogram
- The Abnormal Electrocardiogram
- Future Perspectives
- Guidelines: Electrocardiography
- 15. Exercise Physiology and Exercise Electrocardiographic Testing
- Exercise Physiology
- Technical Components of Exercise Testing
- Exercise Testing in Coronary Artery Disease
- Exercise Testing in Nonatherosclerotic Heart Disease
- Additional Uses for Exercise Testing
- Summary
- 16. Echocardiography
- Principles of Ultrasound and Instrumentation
- The Standard Adult Transthoracic Echocardiographic Examination
- Transesophageal Echocardiography
- Three-Dimensional Echocardiography
- Ultrasound Enhancing Agents
- Myocardial Infarction
- Cardiomyopathies
- Stress Echocardiography
- Valvular Heart Disease (See Part VIII)
- Pericardial Disease (see Chapter 86)
- Diseases of the Aorta (see Chapter 42)
- Pulmonary Hypertension (see Chapter 88)
- Infective Endocarditis (see Chapter 80)
- Cardiac Masses (see Chapter 98)
- Adult Congenital Heart Disease (see Chapter 82)
- Transcatheter Interventions (see Chapters 74 and 78)
- Appropriate Use Criteria
- Appropriate Use Criteria
- 17. Chest Radiography in Cardiovascular Disease
- Overview
- Approach to Cxr Evaluation
- Specific Cardiovascular Conditions
- 18. Nuclear Cardiology
- Principles of Imaging
- Reducing Radiation Dose
- Patient-Centered Clinical Applications
- Machine Learning and Artificial Intelligence
- Translational Molecular Imaging
- 19. Cardiovascular Magnetic Resonance Imaging
- Principles of Magnetic Resonance Imaging
- Clinical Applications of Cmr
- Novel Cmr Imaging Techniques and Future Perspectives
- 20. Cardiac Computed Tomography
- Basics of Cardiac Computed Tomography
- Coronary Artery Calcium Testing
- Coronary Computed Tomography Angiography
- Assessment of Cardiovascular Structure and Function
- Future Directions
- 21. Coronary Angiography and Intravascular Imaging
- Indications for Coronary Angiography
- Coronary Arteriography Technique
- Angiographic Projections
- Coronary Anatomy
- Coronary Artery Anomalies
- Pitfalls of Coronary Angiography
- Angiogram Evaluation
- Syntax Score
- Special Lesion Considerations
- Coronary Intravascular Imaging
- 22. Invasive Hemodynamic Diagnosis of Cardiac Disease
- Introduction to Invasive Hemodynamic Diagnosis of Cardiac Disease
- Normal Right and Left Heart Waveforms and Valvular Hemodynamics Including Hocm (Lvot Gradients)
- Septal Defects and Left-To-Right/Right-To-Left Shunts
- Physiologic and Pharmacologic Maneuvers and PV Loops
- 23. Anesthesia and Noncardiac Surgery in Patients with Heart Disease
- Assessment of Risk
- The Decision to Undergo Diagnostic Testing
- Tests to Improve Identification and Definition of Cardiovascular Disease
- Overview of Anesthesia for Cardiac Patients Undergoing Noncardiac Surgery
- Postoperative Management
- Surveillance and Implications of Perioperative Cardiac Complications
- Strategies to Reduce the Risk Associated With Noncardiac Surgery
- Conclusion
- Part IV. Preventive Cardiology
- 24. The Vascular Biology of Atherosclerosis
- Overview and Background
- Structure of the Normal Artery
- Atherosclerosis Initiation
- Evolution of Atheroma
- Complication of Atherosclerosis
- Special Cases of Arteriosclerosis
- 25. Primary Prevention of Cardiovascular Disease
- Overview
- Cardiovascular Disease Risk Assessment
- Risk Factors for Cardiovascular Disease
- Cardiovascular Prevention in Women (see Chapter 91)
- Lifestyle Factors and Interventions
- Pharmacologic Therapies
- Novel Approaches to Preventive Cardiology
- Gaps in the Evidence and Future Perspectives
- 26. Systemic Hypertension: Mechanisms, Diagnosis, and Treatment
- Definitions of Hypertension
- Epidemiology
- Pathophysiology
- Factors Involved in Predisposition to Hypertension
- A Diagnostic Approach to Primary Hypertension
- Diagnostic Approach for Secondary Hypertension
- Therapeutic Options and Approaches For Primary Hypertension
- Blood Pressure–Lowering Medications
- Therapeutic Options and Approaches for Subgroups Of Hypertension
- Management of Hypertension in Chronic Kidney Disease
- Heart Failure (see Part VI)
- Resistant Hypertension
- Hypertensive Urgency and Emergency
- 27. Lipoprotein Disorders and Cardiovascular Disease
- Lipoprotein Transport System
- Lipoprotein Disorders
- Pharmacologic Management of Lipid Risk
- Clinical Approach to the Treatment of Lipoprotein Disorders
- Future Perspectives
- Guidelines
- Managing Dyslipidemias
- 28. Cardiovascular Disease Risk of Nicotine and Tobacco Products
- Health Effects of Tobacco
- 29. Nutrition and Cardiovascular and Metabolic Diseases
- Energy Balance (see also Chapter 30)
- Foods
- Beverages
- Macronutrients
- Micronutrients
- Dietary Patterns
- Emerging Areas
- Changing Behavior
- 30. Obesity: Medical and Surgical Management
- Epidemiology
- Visceral Obesity
- Clinical Management of Cardiometabolic Risk
- Severe Obesity: a Rapidly Expanding Subgroup of Obese Patients (See Also Chapters 2 and 25)
- Summary and Perspectives
- 31. Diabetes and the Cardiovascular System
- Scope of the Problem
- Coronary Heart Disease in the Patient With Diabetes
- Heart Failure in the Patient with Diabetes
- Summary and Future Perspectives
- Guidelines
- 32. Exercise and Sports Cardiology
- Historical Perspective
- Cardiovascular Response to Exercise And Exercise Training
- Effects of Habitual Physical Activity on Cardiovascular Risk
- Cardiovascular Risks of Exercise
- Approach to Common Clinical Problems in Sports Cardiology
- Determining Athletic Eligibility
- Conclusion
- 33. Comprehensive Cardiac Rehabilitation
- Evolution of Cardiac Rehabilitation
- Elements of Cardiac Rehabilitation Programs
- Value of Cardiac Rehabilitation
- Future Directions for Cardiac Rehabilitation
- Summary
- 34. Integrative Approaches to the Management of Patients with Heart Disease
- Integrative Cardiology
- Integrative Strategies for Specific Cardiac Conditions
- Integrative Self-Care for the Cardiologist
- Conclusion
- Part V. Atherosclerotic Cardiovascular Disease
- 35. Approach to the Patient with Chest Pain
- Causes of Acute Chest Pain
- Diagnostic Considerations
- Immediate Management
- 36. Coronary Blood Flow and Myocardial Ischemia
- Control of Coronary Blood Flow
- Physiologic Assessment of Coronary Artery Stenoses
- Coronary Collateral Circulation
- Metabolic and Functional Consequences of Ischemia
- Future Perspectives
- 37. ST-Elevation Myocardial Infarction: Pathophysiology and Clinical Evolution
- Changing Patterns in Incidence And Care
- Improvements in Outcome
- Pathologic Findings
- Pathophysiology
- Clinical Features
- Future Perspectives
- 38. ST-Elevation Myocardial Infarction: Management
- Prehospital Management
- Management in the Emergency Department
- Reperfusion Therapy
- Hospital Management
- Hemodynamic Disturbances
- Arrhythmias
- Other Complications
- Convalescence, Discharge, And Post-Myocardial Infarction Care
- Future Perspectives and Emerging Therapies
- 39. Non–ST Elevation Acute Coronary Syndromes
- Epidemiology
- Pathophysiology
- Clinical Assessment
- Imaging
- Risk Assessment
- Management
- Groups of Special Interest
- Future Perspectives
- Guidelines
- 40. Stable Ischemic Heart Disease
- Magnitude of the Problem
- Stable Angina Pectoris
- Evaluation and Management
- Other Manifestations of Coronary Artery Disease
- Future Perspectives
- 41. Percutaneous Coronary Intervention
- Background
- Indications
- Coronary Devices
- Mechanical Circulatory Support (also see Fig. 41.7 and “Role of Left Ventricular Dysfunction in PCI”; see Chapter 59)
- Vascular Access
- Antiplatelet Agents (See Also CHAPTERS 9, 38, 39, 40)
- Antithrombin Agents (see CHAPTERS 9, 38,AND 39)
- Outcomes After Percutaneous Coronary Intervention
- Future Perspectives
- 42. Diseases of the Aorta
- The Normal Aorta
- Aortic Aneurysms
- Aortic Dissection
- Aortic Dissection Variants
- Aortoarteritis Syndromes
- Primary Tumors of the Aorta
- Future Perspectives
- 43. Peripheral Artery Diseases
- Epidemiology
- Clinical Features
- Testing for Peripheral Artery Disease
- Other Measurement Tools
- Prognosis
- Treatment
- Treatment of Symptoms and Prevention of Limb Vascular Events
- Vasculitis (See also Chapter 97)
- Takayasu Arteritis and Giant Cell Arteritis (See Chapter 97)
- Popliteal Artery Entrapment Syndrome
- Acute Limb Ischemia
- Atheroembolism
- 44. Treatment of Noncoronary Obstructive Vascular Disease
- Approach to the Patient with Peripheral Artery Disease
- Endovascular Technologies
- Planning an Intervention
- Endovascular Treatment of Arterial Disease
- Endovascular Treatment of Venous Disease
- Future Perspectives
- 45. Prevention and Management of Ischemic Stroke
- Classification of Ischemic Stroke
- Stroke Risk Factors and Prevention
- Antithrombotic Agents for Stroke Prevention
- Management of Acute Ischemic Stroke
- Diagnosis and Treatment Of Patients with a Transient Ischemic Attack
- Conclusions
- Part VI. Heart Failure
- 46. Mechanisms of Cardiac Contraction and Relaxation
- Microanatomy of Contractile Cells and Proteins
- Calcium Ion Fluxes in Cardiac Contraction-Relaxation Cycle
- Sarcolemmal Control of Ca2+ and Na+
- Adrenergic Signaling Systems
- Cholinergic and Nitric Oxide Signaling
- Contractile Performance of the Heart
- Future Perspectives
- 47. Pathophysiology of Heart Failure
- Pathogenesis
- Vasoconstricting Peptides in Heart Failure
- Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases
- Reversibility of Left Ventricular Remodeling and Recovery of Left Ventricular Function
- Future Perspectives
- 48. Approach to the Patient with Heart Failure
- Heart Failure Definition and Epidemiology
- The Medical History and Physical Examination
- Routine Laboratory Assessment
- Risk Scoring for Prognosis
- Right Heart Catheterization
- Endomyocardial Biopsy
- Detecting Comorbid Conditions
- Assessment of Quality of Life
- Cardiopulmonary Exercise Testing
- Use of Imaging Modalities in the Diagnosis and Management of Patients With Heart Failure
- Timing of Advanced Heart Failure Referral
- Summary and Future Perspectives
- 49. Diagnosis and Management of Acute Heart Failure
- Epidemiology
- Pathophysiology
- Evaluation of the Acute Heart Failure Patient
- Management of the Patient with Acute Heart Failure
- Future Perspectives
- 50. Management of Heart Failure Patients with Reduced Ejection Fraction
- Etiology
- Prognosis
- Approach to the Patient
- Management of Fluid Retention
- Prevention of Disease Progression (TABLE 50.7 and Fig. 50.10)
- Management of Patients who Remain Symptomatic
- Pharmacogenomics/Personalized Medicine
- Management of Atherosclerotic Disease
- Management of Valvular Disease
- Special Populations
- Anticoagulation and Antiplatelet Therapy
- Management of Cardiac Arrhythmias
- Device Therapy
- Sleep-Disordered Breathing
- Disease Management
- Patients With Refractory End-Stage Heart Failure (Stage D)
- Integration of Palliative Care Into Heart Failure Care
- Future Perspectives
- Pharmacogenomics (see Chapter 9)
- Digoxin
- End of Life Care
- 51. Heart Failure with Preserved and Mildly Reduced Ejection Fraction
- Epidemiology
- Diagnosis
- Pathophysiology
- Treatment of HFpEF and HFmrEF
- 52. The Dilated, Restrictive, and Infiltrative Cardiomyopathies
- The Dilated Cardiomyopathies
- Restrictive and Infiltrative Cardiomyopathies
- Future Perspectives
- 53. Cardiac Amyloidosis
- Epidemiology
- Pathophysiology
- Clinical Features and Prognosis
- Diagnosis
- Clinical Management
- Conclusion
- 54. Hypertrophic Cardiomyopathy
- Diagnosis, Morphology, and Etiology of Hypertrophic Cardiomyopathy
- Pathophysiology
- Natural History
- Genetic Testing and Family Management
- Clinical Management
- Patients With Obstructive Hypertrophic Cardiomyopathy
- Patients With Nonobstructive Hypertrophic Cardiomyopathy
- Clinical Trials and Emerging Therapies
- Summary
- 55. Myocarditis
- Overview and Definition
- Epidemiology
- Specific Etiologic Agents
- Human Immunodeficiency Virus (see Chapter 85)
- Pathogenesis of Viral Myocarditis
- Helminths
- Additional Physical Agents That Cause Myocarditis
- MicroRNAs in Myocarditis
- The Role of Innate Immunity In Myocarditis
- Specific Clinical Presentations of Myocarditis
- Diagnostic Approaches
- Prognosis
- Treatment
- Future Perspectives
- 56. Cardio-Oncology: Managing Cardiotoxic Effects of Cancer Therapies
- Epidemiology, Clinical Manifestations, and Pathophysiology of Cancer Therapy Cardiotoxicity
- Genetics of Anthracycline Cardiotoxicity
- Immunotherapy
- Targeted Therapy
- Hormonal Therapy
- Radiation Therapy
- Stem Cell Transplantation
- Mechanistic Overlap Between Cardiovascular Disease and Cancer
- Future Perspectives
- Mechanistic Overlap Between Cardiovascular Disease and Cancer
- 57. Cardio-Oncology: Approach to the Patient
- Approach to the Cancer Patient at Risk of or with Cardiovascular Diseases Before Cancer Therapy
- Approach to the Cancer Patient at Risk of or with Cardiovascular Diseases During Cancer Therapy
- Approach to the Cancer Patient at Risk of or with Cardiovascular Diseases After Cancer Therapy
- Cardio-Oncology Care Team and Clinics
- Future Perspectives
- Approach to the Cancer Patient at Risk of or with Cardiovascular Diseases Before Cancer Therapy
- 58. Devices for Monitoring and Managing Heart Failure
- Ventricular Dyssynchrony: The Target of Cardiac Resynchronization Therapy
- Sudden Cardiac Death in Chronic Heart Failure
- Guidelines for Cardiac Resynchronization and Implantable Cardioverter-Defibrillators in Heart Failure With A Reduced Ejection Fraction
- New Implantable Therapeutic Devices for Heart Failure (Table 58.3)
- Implantable Devices to Monitor Heart Failure
- Interplay Between Drugs and Devices
- Conclusions
- 59. Mechanical Circulatory Support
- Indications, Strategies, and Device Selection
- Design of Ventricular Assist Devices
- Engineering Designs of Ventricular Assist Devices
- Patient Selection, Comorbidity, and Timing of Intervention
- Patient Outcomes
- Patient Selection, Comorbidity, and Timing of Intervention
- 60. Cardiac Transplantation
- Historical Aspects
- Epidemiology of Heart Transplantation
- Evaluation of the Potential Recipient
- Donor Allocation System
- The Cardiac Donor
- Surgical Considerations
- Immunosuppression
- Rejection
- Outcomes After Heart Transplantation
- Infection
- Medical Complications and Comorbid Conditions
- Future Perspectives
- Part VII. Arrhythmias, Sudden Death, and Syncope
- 61. Approach to the Patient with Cardiac Arrhythmias
- General Approach to the History and Physical Exam
- Signs and Symptoms
- Clinical and Laboratory Testing
- Head Up Tilt
- Guidelines
- 62. Mechanisms of Cardiac Arrhythmias
- Foundations of Cardiac Electrophysiology
- Structure and Function of the Cardiac Electrical Network
- Mechanisms Of Arrhythmogenesis
- 63. Genetics of Cardiac Arrhythmias
- The QT-Opathies
- The Other Channelopathies
- Conclusions
- Future Perspectives
- 64. Therapy for Cardiac Arrhythmias
- Pharmacologic Therapy
- Electrotherapy for Cardiac Arrhythmias
- Surgical Therapy for Tachyarrhythmias
- 65. Supraventricular Tachycardias
- Definitions
- Assessment of the Patient With Palpitations
- Supraventricular Arrhythmia Types
- Differential Diagnosis of Wide Complex Tachycardia
- 66. Atrial Fibrillation: Clinical Features, Mechanisms, and Management
- Electrocardiographic Features
- Classification of Atrial Fibrillation
- Epidemiology of Atrial Fibrillation
- Mechanisms of Atrial Fibrillation
- Genetic Factors
- Causes of Atrial Fibrillation
- Clinical Features
- Diagnostic Evaluation
- Prevention of Thromboembolic Complications
- Acute Management of Atrial Fibrillation
- Long-Term Management of Atrial Fibrillation
- Nonpharmacologic Management of Atrial Fibrillation
- Specific Clinical Syndromes
- Future Perspectives
- Guidelines
- 67. Ventricular Arrhythmias
- Premature Ventricular Complexes, Nonsustained Ventricular Tachycardias, Couplets
- Accelerated Idioventricular Rhythm
- Sustained Ventricular Tachycardia
- Ventricular Fibrillation
- Ventricular Flutter
- 68. Bradyarrhythmias and Atrioventricular Block
- Bradyarrhythmias
- Atrioventricular Block (Heart Block)
- Atrioventricular Dissociation
- 69. Pacemakers and Implantable Cardioverter-Defibrillators
- Types of Devices
- Device Radiography
- Types of Pacemakers
- Indications for Pacemakers
- Capture and Sensing
- Pacing Mode and Timing Cycles
- Implantable Cardioverter-Defibrillators
- ICD System Selection
- ICD Therapy
- ICD Troubleshooting
- Complications
- Follow-Up and Management
- 70. Cardiac Arrest and Sudden Cardiac Death
- Perspective
- Definitions
- Epidemiology
- Causes of Sudden Cardiac Death
- Clinical Features of Patients with Cardiac Arrest
- Management of Cardiac Arrest
- Prevention of Cardiac Arrest and Sudden Cardiac Death
- Sudden Death and Public Safety
- 71. Hypotension and Syncope
- Definition
- Classification
- Vascular Causes of Syncope
- Cardiac Causes of Syncope
- Neurologic Causes of Transient Loss of Consciousness
- Metabolic Causes of Transient Loss of Consciousness
- Diagnostic Tests
- Approach to the Evaluation of Patients With Syncope
- Management of Patients With Syncope
- Cardioneuroablation for Treatment of Neurally Mediated Syncope
- Future Perspectives
- Part VIII. Diseases of the Heart Valves
- 72. Aortic Valve Stenosis
- Epidemiology
- Causes and Etiology
- Clinical Presentation
- Disease Course and Staging
- Treatment
- 73. Aortic Regurgitation
- Causes and Pathology
- Chronic Aortic Regurgitation
- Acute Aortic Regurgitation
- 74. Transcatheter Aortic Valve Replacement
- Epidemiology, Natural History, and Treatment Alternatives for Valvular Aortic Stenosis
- History and Background of Transcatheter Aortic Valve Replacement (TAVR)
- The Early Years of TAVR
- TAVR Evidence-Based Clinical Research
- TAVR Technology Evolution
- TAVR Procedural Maturation
- TAVR-Associated Complications
- TAVR and Concomitant Cardiac Diseases
- TAVR in Surgical Bioprosthetic Aortic Valve Failure
- Gaps in TAVR Knowledge and Ongoing Controversies
- Future TAVR Directions
- Next Generation Valve Technology
- Expanded Clinical Indications
- The Modern Era Heart Team
- 75. Mitral Stenosis
- Epidemiology and Secular Trends
- Definition of Disease and Severity
- Rheumatic Mitral Stenosis
- Nonrheumatic Mitral Stenosis
- 76. Mitral Regurgitation
- Mitral Valve Anatomy
- Mechanisms of Mitral Regurgitation
- Primary Mitral Regurgitation
- Secondary Mitral Regurgitation
- 77. Tricuspid, Pulmonic, and Multivalvular Disease
- Tricuspid Stenosis
- Tricuspid Regurgitation
- Pulmonic Stenosis
- Pulmonic Regurgitation
- Multivalvular Disease
- 78. Transcatheter Therapies for Mitral and Tricuspid Valvular Heart Disease
- Mitral Stenosis (See Chapter 75)
- Mitral Regurgitation
- Tricuspid Regurgitation
- Summary
- Conclusion
- 79. Prosthetic Heart Valves
- Types of Prosthetic Heart Valves
- Medical Management and Surveillance After Valve Replacement
- Evaluation and Treatment of Prosthetic Valve Dysfunction and Complications
- 80. Infectious Endocarditis and Infections of Indwelling Devices
- Infective Endocarditis
- Cardiovascular Implantable Electronic Device Infections
- Left Ventricular Assist Device Infections
- Guidelines
- Guidelines
- 81. Rheumatic Fever
- Epidemiology
- Pathogenesis
- Clinical Features
- Diagnosis
- Natural History
- Management
- Prevention
- Future Perspectives
- Part IX. Diseases of the Myocardium, Pericardium, and Pulmonary Vasculature Bed
- 82. Congenital Heart Disease in the Adolescent and Adult
- General Considerations
- Congenital Anatomy
- Long-Term Considerations
- Specific Defects
- Pulmonary Hypertension and Eisenmenger Syndrome
- 83. Catheter-Based Treatment of Congenital Heart Disease in Adults
- Valvular Interventions
- Arterial Interventions
- Septal Interventions
- Future Perspectives
- 84. Cardiomyopathies Induced by Drugs or Toxins
- Alcohol
- Electronic Cigarettes
- Cocaine
- Marijuana
- Energy Drinks And Caffeine
- Opiates
- Heavy Metals
- Future Directions
- Acknowledgment
- 85. Cardiovascular Abnormalities in HIV-Infected Individuals
- Cardiovascular Risk Factors in People Living With Hiv
- Mechanisms of Hiv-Related Atherogenesis
- Coronary Disease in Hiv Subjects
- Risk Assessment and Screening for Coronary Disease
- Other Cardiovascular Conditions Associated With Hiv
- 86. Pericardial Diseases
- Acute Pericarditis
- Pericardial Effusion and Cardiac Tamponade
- Constrictive Pericarditis
- Effusive-Constrictive Pericarditis
- 87. Pulmonary Embolism and Deep Vein Thrombosis
- Epidemiology
- Pathophysiology
- Classification of Pulmonary Embolism
- Diagnosis
- Therapy
- Optimal Duration of Anticoagulation and Selection of Optimal Anticoagulant
- Advanced Therapy for Acute Pulmonary Embolism
- Prevention
- Future Perspectives
- 88. Pulmonary Hypertension
- Normal Pulmonary Circulation
- Classification of Pulmonary Hypertension
- Pathology
- Pathobiology
- Patient Presentation and Clinical Assessment
- Integrated Approach to Diagnosing Pulmonary Hypertension
- Treatment
- Special Clinical Circumstances
- Future Perspectives
- 89. Sleep-Disordered Breathing and Cardiac Disease
- Definitions
- Pathophysiology
- Sleep-Disordered Breathing and Hypertension
- Sleep-Disordered Breathing and Coronary Heart Disease
- Sleep-Disordered Breathing, Cardiac Function, and Heart Failure
- Sleep-Disordered Breathing and Cardiac Arrhythmias
- Future Perspectives
- Part X. Cardiovascular Disease in Select Populations
- 90. Cardiovascular Disease in Older Adults
- What is aging?
- Age-Associated Changes in Cardiovascular Structure and Function
- Geriatric Domains Pertinent to Cardiovascular Care
- Precepts of Patient-Centered Care in Older Adults
- Coronary Heart Disease
- Acute Coronary SyndromeS (ACS) (See Chapters 37 to 39)
- Heart Failure
- Valvular Heart Disease (see PART VIII)
- Cardiac Rhythm Abnormalities
- Venous Thromboembolic Disease
- Syncope
- Prevention
- Noncardiac Surgery and Perioperative Management Considerations in Older Adults
- Peripheral Arterial Disease, Abdominal Aortic Aneurysm, Aortic Dissection
- 91. Cardiovascular Disease in Women
- Background
- Sex, Gender, and Genetic Differences in Cardiovascular Disease
- Cardiovascular Risk Factors in Women (see Chapters 25 and 30)
- Cardiovascular Disease Risk Assessment (see also Chapter 25)
- Ischemic Heart Disease in Women
- Ischemic Heart Disease: Beyond Obstructive Coronary Artery Disease
- Cardiac Surgery
- Peripheral Arterial Disease (see also Chapter 43)
- Heart Failure (see also Chapters 47–52)
- Arrythmia and Sudden Cardiac Death
- Cardiovascular Disease Prevention
- 92. Pregnancy and Heart Disease
- Cardiovascular Changes in Pregnancy
- Evaluation Prior to Pregnancy and During Pregnancy
- General Management Principles
- Specific Cardiovascular Conditions
- Cardiomyopathies (see Part VI)
- Myocardial Infarction and Ischemic Heart Disease
- Native Valvular Heart Disease (see Part VIII)
- Prosthetic Valves and Management of Anticoagulation
- Arrhythmias (see Part VII)
- Congenital Heart Disease (see Chapter 82)
- Pulmonary Hypertension
- Marfan Syndrome and Inherited Aortopathies
- Contraception
- 93. Heart Disease in Racially and Ethnically Diverse Populations
- Epidemiology of Cardiovascular Disease in Heterogeneous Populations
- Cardiovascular Disease Management
- Potential for Emerging Scientific Research to Address Group Disparities in Cardiovascular Disease
- Part XI. Cardiovascular Disease and Disorders of Other Organs
- 94. Endemic and Pandemic Viral Illnesses and Cardiovascular Disease: Influenza and COVID-19
- Introduction
- Influenza and Cardiovascular Risk and Disease
- SARS-CoV-2 and COVID-19
- 95. Hemostasis, Thrombosis, Fibrinolysis, and Cardiovascular Disease
- Hemostatic System
- Thrombosis
- Treatment of Thrombosis
- Future Perspectives
- 96. Endocrine Disorders and Cardiovascular Disease
- Pituitary Hormones and Cardiovascular Disease
- Adrenal Hormones and Cardiovascular Disease
- Pheochromocytoma and Paraganglioma
- Parathyroid Hormone and Cardiovascular Disease
- Thyroid Hormone and Cardiovascular Disease
- Future Perspectives
- 97. Rheumatic Diseases and the Cardiovascular System
- Atherosclerosis and the Rheumatic Diseases
- Vasculitides (See Chapters 42 and 43)
- Pericarditis and Myocarditis
- Valvular Heart Disease
- Cardiac Conduction Disturbances
- Pulmonary Arterial Hypertension
- Thrombosis in the Rheumatic Diseases (See Also Chapter 95)
- Antirheumatic Drugs and Cardiovascular Disease
- Future Perspectives
- 98. Tumors Affecting the Cardiovascular System
- Clinical Manifestation of Cardiac Tumors
- Benign (Nonmalignant) Primary Cardiac Tumors
- Malignant Primary Cardiac Tumors
- Secondary Cardiac Tumors
- Direct and Indirect Complications of Neoplasia
- Future Perspectives
- Treatment of Sarcomas
- The Superior Vena Cava Syndrome in Cancer Patients
- 99. Psychiatric and Psychosocial Aspects of Cardiovascular Disease
- Acute Stress and Emotional Arousal
- Cardiovascular Consequences of Chronic Stress (see also Chapter 93)
- Mental Health and Psychiatric Disorders
- Evaluation and Management of Mental Health in the Cardiac Patient
- Summary and Future Directions
- Alternative Medicines and Supplements for Depression and Anxiety
- 100. Neuromuscular Disorders and Cardiovascular Disease
- Neuromuscular Diseases
- Muscular Dystrophies
- Less Common Neuromuscular Diseases Associated with Cardiac Manifestations
- Conclusions/Future Perspectives
- 101. Interface Between Renal Disease and Cardiovascular Illness
- The Cardiorenal Intersection
- Chronic Kidney Disease and Cardiovascular Risk
- Implications of Anemia Due to Chronic Kidney Disease
- Contrast-Induced Acute Kidney Injury (see also Chapter 21 and Fig. 21.2)
- Prevention of Contrast-Induced Acute Kidney Injury
- Cardiac Surgery Associated Acute Kidney Injury
- Acceleration of Vascular Calcification
- Renal Disease and Hypertension (See Also Chapter 26)
- Diagnosis of Acute Coronary Syndromes in Patients with Chronic Kidney Disease (See Also Chapters 38 And 39)
- Renal Dysfunction as a Prognostic Factor in Acute Coronary Syndromes (See Also Chapters 35, 38, And 39)
- Reasons for Poor Outcomes After Acute Coronary Syndromes in Patients with Renal Dysfunction
- Treatment of Myocardial Infarction in Patients with Renal Dysfunction (See Chapters 38 And 39)
- Cardiorenal Syndromes (See PART VI)
- Chronic Kidney Disease and Valvular Heart Disease (See Part VIII)
- Renal Function and Arrhythmias (See Part VII)
- Consultative Approach to Severe Kidney Disease and Hemodialysis Patients
- Evaluation and Management of the Renal Transplant Recipient
- Summary
- 102. Cardiovascular Manifestations of Autonomic Disorders
- Overview of Anatomy and Physiology of the Autonomic Nervous System
- Pathophysiology
- Proarrhythmia
- Investigations and Diagnosis
- Neuromodulatory Therapies
- Future Perspectives
- Disclosure Index
- Index
- No. of pages: 2034
- Language: English
- Edition: 12
- Published: October 15, 2021
- Imprint: Elsevier
- Hardback ISBN: 9780323722193
- Hardback ISBN: 9780323824675
- Hardback ISBN: 9780323824682
- eBook ISBN: 9780323824712
RB
Robert O. Bonow
Affiliations and expertise
Northwestern University, Feinberg School of MedicineDM
Douglas L. Mann
Affiliations and expertise
Washington University, School of MedicineGT
Gordon F. Tomaselli
Affiliations and expertise
Executive Vice President; Chief Academic Officer; Dean Montefiore Medicine; Professor, Department of Medicine Einstein College of Medicine, Yeshiva University, Bronx, New YorkDB
Deepak L. Bhatt
Affiliations and expertise
Executive Director of Interventional Cardiovascular Programs, Brigham and Women’s Hospital Heart and Vascular Center; Professor of Medicine, Harvard Medical School, Boston, MassachusettsSS
Scott D. Solomon
Affiliations and expertise
Brigham and Women’s Hospital, Harvard Medical School, Boston, MassachusettsEB
Eugene Braunwald
Dr. Eugene Braunwald, an Elsevier Author, is considered the leading name in cardiology and his research has expanded knowledge and understanding in the areas of congestive heart failure, coronary artery disease, and valvular heart disease. He has authored more than 1400 medical articles and his textbook, Braunwald’s Heart Disease, is cited worldwide and recognized as the best book on the subject.
Affiliations and expertise
Distinguished Hersey Professor of Medicine, Harvard Medical School, Founding Chairman, TIMI Study Group, Brigham and Women ’s Hospital, Boston, Massachusetts, USAPL
Peter Libby
Dr. Peter Libby is a cardiovascular medicine specialist at Brigham and Women’s Hospital and Mallinckrodt Professor of Medicine at Harvard Medical School (HMS). Receiving his medical degree from the University of California, San Diego School of Medicine, he undertook a cellular physiology research fellowship at HMS. After a residency in internal medicine and a fellowship in cardiovascular disease, he became board certified in both. He is an editor of the leading cardiovascular medicine textbook, and the author of over 500 peer-reviewed publications, 575 reviews, chapters, etc. He has received funding from the American Heart Association (AHA) and National Institutes of Health, plus recognitions on four continents, including the AHA and American College of Cardiology’s highest research awards, the Gold Medal of the European Society of Cardiology, the Anitschkow award from the European Atherosclerosis Society, the Ernst Jung Gold Medal for Medicine, and the Earl Benditt award for vascular biology.
Affiliations and expertise
Brigham and Women’s Hospital, Harvard Medical School, USA